New large-scale DNA manufacturing facility in the UK Touchlight, a UK-based manufacturer of synthetic DNA, has received the first phase of planning approval for breaking ground on its new research and manufacturing facility in Hampton, UK. The project will include the repair and renovation of a key remaining part of…..
Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology
Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology Collaboration combines Intellia’s proprietary genome editing technology platform with SparingVision’s significant ophthalmology expertise Intellia will grant SparingVision exclusive rights to its leading in vivo CRISPR/Cas9 technology for the development of ocular therapies directed to three…..
Boehringer Ingelheim to expand veterinary vaccine capacity for emerging and transboundary diseases in France
Boehringer Ingelheim to expand veterinary vaccine capacity for emerging and transboundary diseases in France Boehringer Ingelheim announced an additional €100 million investment in its veterinary public health capabilities in Lyon-Jonage, France, to aid governments and public health organizations in managing future emerging and transboundary diseases. Transboundary and emerging diseases are…..
Germany approves Rheacell’s cell therapy product Amesanar® for the use in patients with chronic wounds
Germany approves Rheacell's cell therapy product Amesanar® for the use in patients with chronic wounds Chronic wounds not only put great strain on the health system, but also have a major impact on the quality of life of affected patients. Rheacell, a German biopharmaceutical company focused on clinical development of…..
License Option Agreement with Pfizer for Voyager Therapeutic's Next-Generation TRACERᵀᴹ AAV Capsids Voyager Therapeutics, a gene therapy company developing adeno-associated virus (AAV) platform technologies, announced an agreement through which Pfizer may exercise options to license novel capsids generated from Voyager’s RNA-driven TRACERTM (Tropism Redirection of AAV by Cell-type-specific Expression of…..
Envisagenics Raises Series A Financing to Scale its AI-powered RNA Splicing Drug Discovery Platform Envisagenics, an Artificial Intelligence-driven biotechnology company focused on the discovery and development of novel RNA splicing therapeutics, secured Series A financing to scale its drug discovery platform and biopharmaceutical partnerships. Red Cell Partners led the financing,…..